Publication date: Jun 01, 2025
Recently, we reported that the SARS-CoV-2 nucleocapsid (N) protein triggers DNA damage by inducing autophagic degradation of RNAi components (Dicer and XPO5) and splicing factors (SRSF3 and hnRNPA3). In this study, we found that the SARS-CoV-2 N protein synergizes with chemotherapeutics to induce DNA damage and activate the cGAS-STING pathway in NSCLC cells. Moreover, the SARS-CoV-2 N protein acts synergistically with chemotherapeutics to suppress the proliferation and colony formation of NSCLC cells. Finally, we demonstrated that the SARS-CoV-2 N protein enhances the antitumor effects of etoposide in xenograft tumor mouse model. These findings reveal a novel antitumor mechanism of the SARS-CoV-2 N protein, positioning it as a potential therapeutic agent for lung cancer patients.
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | protein |
disease | MESH | DNA damage |
disease | IDO | colony |
drug | DRUGBANK | Etoposide |
disease | MESH | tumor |
disease | MESH | lung cancer |
disease | MESH | Carcinoma Non-Small-Cell Lung |
disease | IDO | cell |
disease | MESH | COVID-19 |